Posts
Displaying 1 - 1 of 1 results
Emerging Health Care Innovation Brief: Treating Post-COVID Conditions and Preventing Fetal and Neonatal Alloimmune Thrombocytopenia
Highlight
The latest Emerging Health Care Innovation Brief looks at IMC-2 (Valacyclovir plus Celecoxib), an investigational treatment for patients who develop post-COVID conditions. The brief also looks at RLYB212, an experimental…